The University of Chicago Header Logo

Connection

Mitchell C. Posner to Oncolytic Virotherapy

This is a "connection" page, showing publications Mitchell C. Posner has written about Oncolytic Virotherapy.
Connection Strength

0.212
  1. Tumor genotype determines susceptibility to oncolytic herpes simplex virus mutants: strategies for clinical application. Future Oncol. 2007 Oct; 3(5):545-56.
    View in: PubMed
    Score: 0.074
  2. Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity. Cancer Res. 2007 Sep 01; 67(17):8301-6.
    View in: PubMed
    Score: 0.073
  3. Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1. J Virol. 2006 Feb; 80(3):1110-20.
    View in: PubMed
    Score: 0.066
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.